Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia

Among adults with relapsed acute lymphoblastic leukemia, treatment with the anti-CD22 drug conjugate inotuzumab ozogamicin produced a higher rate of complete remission, as well as a higher rate of veno-occlusive disease, than did standard chemotherapy. An estimated 2650 adults in the United States received a new diagnosis of acute lymphocytic leukemia (ALL) in 2015; the prognosis for these patients remains poor. 1 Current therapies for adults with newly diagnosed B-cell ALL are associated with rates of complete remission of 60 to 90%. 2 – 9 However, many of the patients with complete remission will have a relapse, and only approximately 30 to 50% will have disease-free survival lasting 3 years or longer. 5 – 9 Current standard chemotherapy regimens for adults with relapsed or refractory B-cell ALL are associated with rates of complete remission of 31 to 44% when they . . .